On April 8, 2019 PharmaMar (MSE:PHM) reported that attended the third bi-annual meeting on small cell lung cancer, organized by the International Association for the Study of Lung Cancer (IASLC) (Press release, PharmaMar, APR 8, 2019, View Source [SID1234535048]). During this meeting, Anna Farago M.D., Ph.D., coPrincipal Investigator of the ATLANTIS trial from Massachusetts General Hospital in Boston, presented the latest data from the ATLANTIS trial with Zepsyre (lurbinectedin) in combination with doxorubicin for the treatment of recurrent small cell lung cancer, in an oral presentation on Friday 5th April. This is a specialized meeting, which presents information on the clinical trials of the most promising therapies for the treatment of small cell lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ATLANTIS trial of lurbinectedin in combination with doxorubicin compared to topotecan or the combination CAV (cyclophosphamide, adriamycin and vincristine), randomized 1 to 1, recruited 613 patients in 160 centers in 20 countries, with Spain, Germany and the United States the countries with the highest number of patients recruited. The primary objective of the study is overall survival (OS).

Also for the treatment of second line small cell lung cancer, PharmaMar recently announced positive results for its monotherapy trial with lurbinectedin. The results of this study will be made public during an oral presentation at the next ASCO (Free ASCO Whitepaper) congress.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.